By Israel Rocha, CEO, Doctors Hospital at Renaissance
September 15 marks the beginning of Hispanic Heritage Month, a time to pay tribute to the generations of Hispanics who have enriched America’s history. It’s also an important time to consider how this community can be further empowered to make important contributions, particularly in the future of health care.
Research demonstrates that certain diseases disproportionately impact the Hispanic community, including diabetes, liver cancer, cervical cancer and HIV/AIDS. Clinical trials help researchers find better ways to diagnose, prevent and treat these diseases and others. However, Hispanics are significantly underrepresented in clinical trials. Despite representing 16 percent of the U.S. population, Hispanics comprise only 1 percent of clinical trial participants.
Given this historic underrepresentation, there is tremendous opportunity to boost clinical trial participation within diverse patient populations. According to a July 2013 study by Research!America:
- More than 40 percent of Hispanics greatly admire clinical trial participants.
- More than 2/3 of Hispanics would be willing to share health information to help researchers find better ways to prevent and treat disease.
- Nearly half of the Hispanics polled rate a physician’s recommendation to participate in a clinical trial as very important.
Stagnant funding could threaten progress in eye research
America’s minority populations are united in the view that not only is eye and vision research very important and needs to be a national priority, but many feel that current federal funding ($2.10 per person, per year) is not enough and should be increased. This may stem from the evidence that most minority populations recognize to some degree that individuals have different risks of eye disease depending on their ethnic heritage.
And while these Americans rate losing their eyesight as having the greatest impact on their daily life and having a significant impact on their independence, productivity and overall quality of life, 50 percent of Americans who suffer from an eye-related disease are not aware of it.
These statics and more were the topic of discussion at a press event in Washington, D.C., today, where members of the media and leaders in the eye and vision research community gathered to interact with a panel of experts and weigh in on the topic of The Public’s Attitudes about the Health and Economic Impact of Vision Loss and Eye Disease. Continue reading →
Excerpt of a joint op-ed by Research!America President and CEO Mary Woolley and Susan G. Komen President and CEO Judith A. Salerno published in The Huffington Post.
February 23, 1954, was a milestone in the history of American medical research. That day, children at Arsenal Elementary School in Pittsburgh lined up to receive injections of a promising vaccine. Within months, schoolchildren all over the country were doing the same, and polio was on its way to being eradicated in the United States. The disease, which had killed and paralyzed children and adults alike, would no longer be a threat.
This remarkable achievement would not have been possible without the work of Dr. Jonas Salk and his team at the University of Pittsburgh, and — equally significant — grant support from the National Foundation for Infantile Paralysis, now known as March of Dimes. Policymakers played a role, too, when the Polio Vaccine Assistance Act of 1955 made possible federal grants to the states for purchase of the vaccine and for the costs of planning and conducting vaccination programs.
A generation or two later, millions of individuals worldwide benefited from another major medical breakthrough. Remember when being diagnosed as HIV-positive was an automatic death sentence in the 1980s? Accelerated research supported by the National Institutes of Health (NIH), in partnership with Burroughs Wellcome and Duke University, resulted in the development of AZT, the first drug that slowed the replication of HIV. By 1987, the drug won FDA approval and marked the first major treatment in extending the lives of HIV/AIDS patients. Continue reading →
Op-ed by Research!America Chair The Hon. John E. Porter published in The Huffington Post.
Why has science become a take-it-or-leave-it proposition for many Americans? Given all that has been accomplished thanks to our nation’s investment in medical research, the value proposition should be ingrained in the public consciousness — reductions in deaths from heart disease and stroke, the eradication of polio in industrialized nations, transformation of HIV/AIDS from a death sentence to a manageable chronic illness, a sense of justifiable optimism instead of despair when a child receives a cancer diagnosis. So much more is within reach if we summon the public and political will to end Alzheimer’s, prevent diabetes, put more cancers in the history books, effectively address mental illness, provide new medical technologies for our wounded warriors. The list goes on.
What will it take to raise awareness and build a greater appreciation of science among Americans and policymakers? Scientists themselves are the most trusted messengers for research, according to polling commissioned by Research!America, yet they are largely invisible to the public. A majority of Americans cannot name a living scientist and many do not know where research is conducted in the U.S. This underlying knowledge gap has led some to question the value of taxpayer-funded research. “If I can’t see it, it must not exist” has worked against research as anti-government sentiments combined with deficit-reduction imperatives drive decision-making on Capitol Hill. This attitude has led to a dearth in federal R&D investments, policies that hinder private sector innovation, challenges in combating global health threats and unreasonable attacks on behavioral and social sciences research. Federal support for medical and health research has also waned as many elected officials seek to diminish government’s role in accelerating medical progress on the mistaken assumption that the private sector and other entities will bear that responsibility.
Sequestration, the automatic spending cuts that stalled important research across the country, and years of flat-funding as homeland defense swept other priorities aside, have shifted the balance with federal funding for research on a downward trajectory. In reality, the public and private sector work hand-in-hand, relying on the discoveries derived from basic scientific research to develop the next blockbuster drug or medical device that could relieve the suffering of millions of patients; one cannot thrive without the other.
It’s time to recognize how different our lives would be without federally-funded research. Many scientific discoveries supported by the National Institutes of Health, the National Science Foundation and other federal agencies that we take for granted have improved our quality of life and protected us from major health threats. Why would we slow down the march of progress? Scientists can play a major role in ensuring that the American public connects the dots of the research pipeline by describing the importance of research in bringing new therapies and cures to market and reducing inefficiencies in our healthcare system.
Speaking at town hall meetings, at the local chamber of commerce or addressing students are some of the ways scientists can engage with the public and elected officials. Volunteering as a science advisor for candidates running for local or national office will help to enlighten and cultivate individuals who can potentially become champions for science in government. Only then can we expect Americans to rally for science and reject attempts by policymakers and others to undervalue research as a major contributor to our nation’s health, national defense and economic stability.
Also read op-ed by Research!America Board member and American Heart Association CEO Nancy Brown on the importance of medical research, here.
The University of Colorado’s Gates Center for Regenerative Medicine and Stem Cell Biology just announced a potentially game-changing discovery in stem cell research for blood cancers and a whole host of other diseases.
Yosef Refaeli and his research team have found a way to expand blood stem cells. This is big news because blood stem cells can help treat blood cancers like leukemia and lymphoma as well as inborn immunodeficiency diseases such as sickle-cell anemia and autoimmune diseases like multiple sclerosis. But up until now, treatment using blood stem cells has been limited by the number of cells a patient can produce. Hundreds of thousands of Americans could be affected by this discovery.
The research was supported in part by funding from the National Institutes of Health.
The goal now is to move the technology from the lab into clinical trials. Colorado-based biotech company Taiga Biotechnologies is in the process of setting up the trials.
The research was originally published in the academic journal PLOS ONE. Read the paper here.
By Robert Gracy, PhD, CEO of Texas Biomedical Research Institute
Now in its eighth decade of existence, the Texas Biomedical Research Institute in San Antonio, Texas, has a mission “to improve the health of our global community through innovative biomedical research.” Texas Biomed has a breadth and depth of scientific inquiry coupled with an unparalleled collection of research resources, which in combination provides its researchers unique capabilities. Texas Biomed also views partnering with Research!America – a strong advocate for growing our country’s investment in biomedical funding – as retaining an effective ally in maintaining and eventually strengthening the backbone of our country’s preeminent position in the biomedical research field.
In the Department of Genetics, researchers are examining the genes related to complex diseases such as cardiovascular illness, diabetes, obesity, metabolic syndrome, macular degeneration, behavioral and psychiatric disorders, arthritis and osteoporosis – hoping to ultimately provide the foundation of knowledge that can lead to better treatment of these devastating illnesses and to personalize care according to the genetic profile of each patient. Continue reading →
The Centers for Disease Control and Prevention (CDC) sent more than 50 disease detectives and other highly trained experts to West Africa to battle Ebola. While here in the U.S., more than 350 CDC staff are working on logistics, communications, analytics, management and other functions to support the response 24/7 at CDC’s Emergency Operations Center.“We are fulfilling our promise to the people of West Africa, Americans, and the world, that CDC would quickly ramp up its efforts to help bring the worst Ebola outbreak in history under control,” said CDC Director Tom Frieden, MD, MPH. “We know how to stop Ebola. It won’t be easy or fast, but working together with our U.S. and international partners and country leadership, together we are doing it.” Read more here.
Meanwhile, researchers at the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) are studying Ebola and seeking better ways to diagnose and treat the disease. In 2013, the NIAID reported spending $42.49 million on Ebola research. Public-private partnerships are critical to containing and preventing such deadly outbreaks. The NIAID is collaborating with Okairos, a biotech company, to develop Ebola vaccines. The NIH is working with the drugmaker Mapp Biopharmaceutical to scale up production of its Ebola drug Zmapp and partnering with BioCryst to advance the company’s experimental treatments.
Sustained and robust federal funding is needed to respond to global health threats, and to support the development of vaccines to combat Ebola and other deadly diseases. Policymakers must assign a higher priority to medical research to ensure the health and wellness of Americans.
Click here to urge your representatives to support increased funding for federal health agencies in FY15.